Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 45: 976-981, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tong, D.
Right arrow Articles by Zeillinger, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tong, D.
Right arrow Articles by Zeillinger, R.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 1999;45:976-981.)
© 1999 American Association for Clinical Chemistry, Inc.


Articles

BRCA1 Gene Mutations in Sporadic Ovarian Carcinomas: Detection by PCR and Reverse Allele-specific Oligonucleotide Hybridization

Dan Tong1, Margit Stimpfl1, Alexander Reinthaller1, Norbert Vavra1, Silvia Müllauer-Ertl2, Sepp Leodolter1,3 and Robert Zeillinger1,a

1 Department of Obstetrics and Gynecology, Division of Gynecology, and
2 Department of Clinical Pathology, General Hospital of Vienna, University of Vienna, A-1090 Vienna, Austria.

3 Ludwig-Boltzmann Institute for Oncology and Fertility Treatment, A-1090 Vienna, Austria.
a Address correspondence to this author at: General Hospital of Vienna, Department of Obstetrics and Gynecology, Molecular Oncology Group, Währinger Gürtel 18-20, EBO 05, A-1090 Vienna, Austria. Fax 43-1-40400-7832; e-mail robert.zeillinger{at}akh-wien.ac.at

Background: Although germline mutations in BRCA1 play a central role in familial breast and ovarian cancers, to date, no somatic mutations in BRCA1 have been reported in sporadic breast cancer, and only five somatic mutations have been identified in the sporadic ovarian carcinomas. Because loss of heterozygosity appears frequently at the BRCA1 locus in nonfamilial breast and ovarian carcinomas, we searched for mutations in the BRCA1 gene in sporadic ovarian tumors.

Methods: We developed a detection system based on PCR and reverse allele-specific oligonucleotide hybridization on membrane strips for the simultaneous detection of 17 frequently occurring mutations in the BRCA1 gene.

Results: As little as 2% mutant DNA in a sample could be detected. Two of 122 DNA samples isolated from sporadic ovarian tumor biopsies contained the Cys61Gly mutation. Both mutations were germline mutations. One of these was an ovarian metastasis of a primary fallopian tube carcinoma. The tubal carcinoma was also confirmed to contain the Cys61Gly mutation.

Conclusions: This is the first report that a germline BRCA1 mutation is associated with primary tubal carcinoma. The 17 specific mutations in the BRCA1 gene do not play a major role in the tumorigenesis and progression of sporadic ovarian cancer.© 1999 American Association for Clinical Chemistry




The following articles in journals at HighWire Press have cited this article:


Home page
JCOHome page
S. Delaloge, P. Morice, A. Chompret, C. Lhomme, A. Eisen, T. R. Rebbeck, B. L. Weber, and W. C. Wood
Prophylactic Surgery: Oophorectomy or Adnexectomy?
J. Clin. Oncol., October 19, 2000; 18(19): 3454 - 3455.
[Full Text] [PDF]


Home page
Genome ResHome page
H. Tian, L. C. Brody, and J. P. Landers
Rapid Detection of Deletion, Insertion, and Substitution Mutations via Heteroduplex Analysis Using Capillary- and Microchip-Based Electrophoresis
Genome Res., September 1, 2000; 10(9): 1403 - 1413.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.